Business context and reporting period
Entity discrepancy: The supplied filing is Fluidigm Corporation’s Form 10-K, not a filing under the requested company name, STANDARD BIOTOOLS INC. It reports the fiscal year ended December 31, 2017, was signed March 8, 2018, and includes unaudited fourth-quarter results. The summary below reflects the filing as provided.
Fluidigm develops and sells life-sciences research instruments, consumables, assays, and services for genomics, single-cell analysis, and mass cytometry. Products are sold primarily to academic, clinical-research, biopharmaceutical, biotechnology, and agricultural-biotechnology customers.
Financial performance and liquidity
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Total revenue | $101.9 million | $104.4 million |
| Product revenue | $84.4 million | $89.0 million |
| Service revenue | $17.3 million | $15.2 million |
| Operating loss | $58.4 million | $73.2 million |
| Net loss | $60.5 million | $76.0 million |
| Net loss per share | $1.84 | $2.62 |
| Net cash used in operating activities | $24.1 million | $39.1 million |
- Revenue fell 2% year over year; product revenue declined 5%, while service revenue rose 14%. Instrument revenue decreased 9%, largely due to weaker genomics and C1 system sales.
- Product margin fell to 47% from 54%, reflecting lower production volumes, higher excess and obsolete inventory expense, and lower average selling prices. Service margin increased to 72% from 68%.
- Operating expenses decreased 16% to $110.3 million, reflecting cost-reduction measures. Research and development expense was $30.8 million, down 20%.
- Year-end cash and cash equivalents were $58.1 million, with $5.1 million in short-term investments. Working capital, excluding deferred revenue, was $71.6 million, down from $76.3 million.
- Year-end convertible notes had a carrying value of $195.2 million. Contractual debt obligations were reported as $290.3 million, including principal and interest payments.
- Fourth-quarter revenue was $27.7 million and net loss was $10.5 million, versus revenue of $25.1 million and net loss of $17.7 million in Q4 2016.
Material changes versus prior periods
- Revenue declined for a third consecutive year: $114.7 million in 2015, $104.4 million in 2016, and $101.9 million in 2017. Management attributed the longer-term decline largely to lower single-cell genomics instrument sales, competitive pressure, changing demand, and performance issues in certain C1 IFCs.
- Despite lower revenue, net loss narrowed in 2017, alongside expense reductions and lower operating cash use. Cash increased to $58.1 million from $35.0 million, supported in part by equity issuance.
- In August 2017, Fluidigm sold 9.1 million shares through an at-the-market offering, generating approximately $28.8 million net proceeds. Shares outstanding rose to 38.8 million at year-end from 29.2 million.
- International revenue represented approximately 55% of 2017 revenue. U.S. revenue fell 13%; Europe increased 10% and Asia-Pacific increased 8%.
Outlook, risks, contingencies, and unusual items
- Management said existing cash, cash equivalents, and investments were expected to fund working-capital and capital-expenditure needs for at least 18 months. This is not a profitability forecast; the company warned it could require additional financing if losses continue or cash needs exceed expectations.
- In March 2018, after year-end, Fluidigm exchanged approximately $125.0 million principal amount of Original Notes for the same principal amount of new Exchange Notes, leaving approximately $76.3 million of Original Notes. The Exchange Notes have a lower initial conversion price, approximately $7.88 per share, and holder repurchase dates beginning in 2023; their cash repurchase price can reach 120% of outstanding principal plus accrued interest.
- Key operating risks include continued revenue volatility and losses, intense competition, uncertain customer adoption of newer products, dependence on sole- or limited-source suppliers, manufacturing and IFC yield issues, and concentration of manufacturing at facilities in Singapore and Canada.
- Products are labeled for research use only. Changes in regulatory interpretation or customers’ clinical use of the products could trigger additional regulatory obligations or constrain sales.
- The company paid $3.0 million to settle Thermo Fisher litigation in 2017 and received a $1.0 million insurance recovery. Management stated other pending matters were not expected to have a material adverse effect.
- The 2017 Tax Cuts and Jobs Act led to provisional tax accounting; management reported no net tax-provision impact from remeasuring deferred taxes due to a full valuation allowance. The Singapore tax incentive ended after milestones were not met.
- No goodwill impairment was recorded in 2017; goodwill was approximately $104.1 million and net intangible assets approximately $74.2 million. The company identified declines in its stock price, revenue, and market position as potential impairment indicators.
- The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting; management also concluded internal controls were effective as of year-end.
Most important facts for investors to verify
- Confirm the issuer: the supplied 10-K is for Fluidigm Corporation, not Standard BioTools Inc.
- Review the subsequent 2018 note exchange terms, including conversion dilution, repurchase dates, and potential cash obligations.
- Track cash burn, liquidity, and the 18-month funding estimate against subsequent operating results and financing activity.
- Assess whether revenue stabilizes, particularly genomics instrument sales and C1 product performance, and whether mass cytometry growth can offset declines.
- Monitor product margins, inventory reserves, and manufacturing yields, along with reliance on limited-source suppliers.
- Check the final accounting effects of the Tax Act and any future goodwill or intangible-asset impairment charges.